You might also like
GE HealthCare Technologies Inc. is a leading global innovator in medical technology, pharmaceutical diagnostics, and digital solutions . The company operates through four main business segments, offering a wide range of products that support various clinical specialties . These segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, each contributing significantly to the company's overall operations .
-
Imaging - Offers a comprehensive range of products including Molecular Imaging, Computed Tomography, Magnetic Resonance, Image-Guided Therapies, Women’s Health, and X-ray, supporting clinical specialties such as oncology, cardiology, and neurology .
- Molecular Imaging
- Computed Tomography
- Magnetic Resonance
- Image-Guided Therapies
- Women’s Health
- X-ray
-
Ultrasound - Provides solutions for Radiology and Primary Care, Women’s Health, Cardiovascular, and Surgical Visualization and Guidance .
-
Patient Care Solutions (PCS) - Encompasses Patient Monitoring, Anesthesia and Respiratory Care, Diagnostic Cardiology, and Maternal Infant Care .
- Patient Monitoring
- Anesthesia and Respiratory Care
- Diagnostic Cardiology
- Maternal Infant Care
-
Pharmaceutical Diagnostics (PDx) - Includes Contrast Media and Molecular Imaging business lines, enhancing the diagnostic value of imaging exams .
- Contrast Media
- Molecular Imaging
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Peter J. Arduini ExecutiveBoard | President, Chief Executive Officer, and Director | Board Member at Bristol-Myers Squibb Company; Chairman of the Board at AdvaMed; Director at National Italian American Foundation | Appointed as President and CEO of GEHC in December 2022. Previously CEO of Integra LifeSciences. | |
Adam Y. Holton Executive | Chief People Officer | Board Member at Sierra Delta | Joined GEHC in June 2024. Previously Chief People Officer at Amedisys. | |
Frank R. Jimenez Executive | General Counsel and Corporate Secretary | Board Member at Huntington Ingalls Industries, Equal Justice Works, Yale Law School Fund; Advisory Boards at Columbia University, Yale Law School, University of Miami, National Security Institute | Appointed upon GEHC's spin-off in early 2023. Extensive legal experience. | |
James K. Saccaro Executive | Vice President and Chief Financial Officer | None | Joined GEHC as CFO in June 2023. Previously CFO at Baxter International Inc. | |
Kenneth Stacherski Executive | Chief Global Supply Chain and Service Officer | None | Serving since the Spin-Off in 2023. Previously COO at Array Technologies. | |
Kevin M. O’Neill Executive | President and CEO, Pharmaceutical Diagnostics | None | Serving since 2017, continued role post-spin-off. Previously CFO, Life Sciences Division. | |
Philip Rackliffe Executive | President and CEO, Advanced Visualization Solutions | None | Joined GEHC in July 2024. Previously CEO of IGT business at GEHC. | |
Roland Rott Executive | President and CEO, Imaging | None | Joined GE in 2011, CEO of Ultrasound before Imaging. Entrepreneurial background. | |
Taha Kass-Hout Executive | Chief Science and Technology Officer | Chair of the AdvaMed Digital Health Tech Division Board of Directors | Joined GEHC on January 3, 2023. Previously VP of Machine Learning at Amazon. | |
Thomas J. Westrick Executive | President and CEO, Patient Care Solutions | Dean’s Advisory Board for the Wisconsin School of Business | CEO of Patient Care Solutions since September 2020. Previously led Global Quality and Regulatory Affairs. | |
Anne T. Madden Board | Director | Senior VP and General Counsel at Honeywell; Director at Quantinuum | Director since December 2022. Extensive M&A experience at Honeywell. | |
Catherine Lesjak Board | Director | Director at General Electric, PROS Holdings, SunPower Corporation; Advisory Board Member at Haas School of Business | Director since December 2022. Former CFO at HP Inc. | |
H. Lawrence Culp, Jr. Board | Chairman | Chairman and CEO of General Electric; CEO of GE Aerospace | Chairman of GEHC since December 2022. Also leads GE and GE Aerospace. | |
Phoebe L. Yang Board | Director | Board Member at Doximity, Inc.; Board Trustee at CommonSpirit Health; Member of the Council on Foreign Relations | Director since the Spin-Off. Former GM at Amazon Web Services, Healthcare. | |
Risa Lavizzo-Mourey Board | Lead Director | Board Member at Intel, Merck, Better Therapeutics; Chair of Smithsonian Institution Board of Regents; Governor of TIAA; Trustee of Howard Hughes Medical Institute | Lead Director since the spin-off. Former CEO of Robert Wood Johnson Foundation. | |
Rodney F. Hochman Board | Director | President and CEO of Providence; Board Member of Diversey Holdings, Ltd. | Director since the Spin-Off. CEO of Providence. | |
Tomislav Mihaljevic Board | Director | CEO and President of Cleveland Clinic; Board Co-Chair of US-UAE Business Council | Director since the Spin-Off. CEO of Cleveland Clinic. | |
William J. Stromberg Board | Director | Non-Executive Chair of T. Rowe Price Group; Trustee at Johns Hopkins University | Director since the Spin-Off. Former CEO of T. Rowe Price Group. |
- Given the ongoing delays in China's stimulus funding and the slow recovery you've observed, how confident are you in your mid-term revenue and margin projections, and what specific strategies are you implementing to mitigate prolonged delays in China?
- You've raised the low end of your adjusted EPS guidance despite challenges in China; what gives you confidence in achieving this guidance, and what levers can you pull if conditions in China do not improve as anticipated?
- You anticipate Flyrcado could generate over $500 million annually once infrastructure is in place; can you elaborate on the timeline and key challenges in building out the necessary health system capacity, and how might delays impact your growth expectations?
- With the expected launch of Flyrcado in late Q1 2025 and ongoing work around commercialization, reimbursement, and CMS approvals, what risks could potentially delay the launch or affect the adoption rates of this product?
- Despite strong performance in the U.S. and PDx, your organic revenue growth was only 1% this quarter; what specific strategies are you pursuing to drive higher growth rates amid China headwinds and competitive pressures in the imaging equipment market?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Siemens Healthineers | The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Siemens Healthineers. |
Philips Healthcare | The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Philips Healthcare. |
The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Canon. | |
Mindray | The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include Mindray. |
United Imaging | The global medical technology industry is highly competitive and comprised of global and regional participants of all sizes that can vary by product line. Because of the diversity of our products and offerings, we face a wide variety of competitors, including a broad range of manufacturers, third-party distributors, and service providers. In the industries we serve, we believe our primary global competitors include United Imaging. |
Bayer | In our PDx business segment, we primarily compete with Bayer. |
Bracco | In our PDx business segment, we primarily compete with Bracco. |
Guerbet | In our PDx business segment, we primarily compete with Guerbet. |
In our PDx business segment, we primarily compete with Lantheus. | |
Curium | In our PDx business segment, we primarily compete with Curium. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
MIM Software Inc. | 2024 | Acquired on April 1, 2024 for approximately $259 million upfront with additional potential earn-out and contingent payments totaling up to $36 million; the deal was funded with cash on hand and accounted for as a business combination, with key purchase price allocations including goodwill ($195 million) and other intangibles that enhance GE HealthCare’s imaging and AI solutions. |
Caption Health, Inc. | 2023 | Completed on February 17, 2023, this acquisition involved a $127 million upfront payment, a $10 million holdback, and potential earn-out payments of $13 million; it was structured as a business combination with significant purchase price allocations—goodwill of $94 million and intangible assets of $60 million—to bolster GE HealthCare’s Ultrasound segment with AI-guided ultrasound technology. |
IMACTIS SAS | 2023 | Announced in Q2 2023 as a tuck-in acquisition for a French company specializing in electromagnetic navigation for CT procedures; while the financial terms were not disclosed, the deal strategically strengthens GE HealthCare's CT interventional guidance capabilities and fits its push toward enhanced precision care. |
Recent press releases and 8-K filings for GEHC.
- Robust Q1 Performance: Delivered consolidated revenue of $4.8B with around 3-4% organic growth, a record backlog of $20.6B, and improved net income margin (11.8% vs 8.0%) .
- Strong Operating Results: Achieved adjusted EBIT of $715M, with diluted EPS of $1.23 and adjusted EPS of $1.01 .
- Updated Guidance & Capital Returns: Revised outlook to 2%-3% organic revenue growth, targeting at least $1.2B in free cash flow and authorizing a $1B share buyback, with updated EBIT margin targets .
- Strategic & Product Launch Initiatives: Launched the novel radiopharmaceutical Flyrcado (targeting $30M revenue in 2025) and completed the acquisition of Nihon Medi-Physics to bolster key segments .
- Tariff Impact & Mitigation: Reported a net tariff impact of $0.85 per share in Q1 with proactive supply chain measures .
- Record Orders & Demand: Delivered record double-digit orders growth, reinforcing strong customer demand .
- On March 27, 2025, GE HealthCare entered into two new credit agreements: a $500M 364-Day Revolving Credit Agreement maturing on March 26, 2026 and a $3.0B Credit Agreement maturing on March 27, 2030 with JPMorgan Chase Bank, N.A. as administrative agent.
- These new agreements replace previous facilities—a $1.0B revolving credit facility from December 2024 and a $2.5B credit facility from November 2022—streamlining the Company’s debt structure.